Boston Scientific Corpora... (BSX)

The 2025 Q1 earnings cycle is in full swing. And these three companies posted results that had investors pleased.

Raising guidance? In this uncertainty?

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe...

Stocks near buy points include Charles Schwab, German software leader SAP and MercadoLibre, the so-called Amazon of Latin America,

Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here is how Boston Scientific (BSX) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.